Internal Medicine/Gastroenterology and Hepatology

 

Muhammad Y. Sheikh, MD, FACP, FACG, AGAF

Chief of Hepatology & Director of Clinical Research

Professor of Clinical Medicine and Surgery, UCSF

 

 

 

 

 

 

 

  Medical School: Dow Medical College
  Residency: Indiana University
  Fellowships: Gastroenterology and Transplant Hepatology, University of Louisville Hospital & Jewish Hospital, Louisville, Kentucky
Clinical Nutrition, Beth Israel Deaconess Hospital, Harvard Medical School, Boston, MA
  Board Certified:

Internal Medicine

Gastroenterology

Physician Nutrition Specialist

  Awards and Recognition:

Recipient ofLaureate Award-2012 “ from American College of Physicians, Northern California Chapter.

  Publications:  

Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM. Chronic Hepatitis C Genotype 1 Patients With Insulin Resistance Treated With Pioglitazone and Peginterferon Alfa-2a Plus Ribavirin. Accepted in Hepatology, January 2011.

 

Sheikh MY, Atla PR, Raoufi R, Sadiq H, Sadler PC. Prevalence of Hepatitis B Infection Among Young and Unsuspecting Hmong Blood Donors in the Central California Valley. J Community Health. 2011, Jul 22. {Epub ahead of print; PMID: 21785858}.

 

Sheikh MY, Mouanoutoua M, Walvick MD, Khang L, Singh J, Stoltz S, Mills PK. Prevalence of hepatitis B virus (HBV) infection among Hmong immigrants in the San Joaquin Valley. J Community Health. 2011; 36(1):42-6.

 

Gines P. Watson H, Gerbes A, Vilstrup H, Balamenti S, Policlinico SO, {Sheikh MY}. Satavaptan for management of ascites in cirrhosis. Efficacy and safety across the spectrum of ascites severity. Gut. 2012;61:108-16.

 

Sheikh MY, Raoufi R, Atla PR, Riaz M, Oberer C, Moffett MJ. Prevalence of cirrhosis in patients with thrombocytopenia who receive bone marrow biopsy. Saudi J Gastroenterol. 2012;18(4):257-62.

 

Ratziu V, Sheikh MY, Sanyal AJ, Lim JK, Conjeevaram H, Chalasani N, Abdelmalek M, Bakken A, Renou C, Palmer M, Levine RA, Bhandari BR, Cornpropst M, Liang W, King B, Mondou E, Rousseau FS, McHutchison J, Chojkier M. A Phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology. 2012;55(2):419-28

 

Sheikh MY, Atla PR, Raoufi R, Sadiq H, Sadler PC. Prevalence of hepatitis B infection among young and unsuspecting Hmong blood donors in the Central California Valley. J Community Health. 2012;37(1):181-5

 

Sheikh MY, Atla PR, Ameer A, Sadiq H, Sadler PC. Seroprevalence of Hepatitis B and C Infections among Healthy Volunteer Blood Donors in the Central California Valley. Gut Liver. 2013;7(1):66-73.

 

Mathur J, Guthrie JD, Javed U, Sheikh MY. Evaluation of the Association between Compensated Hepatitis C Infectivity and Endothelial Dysfunction, Using Flow-Mediated Vasodilatation of the Brachial Artery. Journal of Diagnostic Medical Sonography 2014 30: 187-192.

 

Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, Bortey E, Forbes WP. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2014; (8):1390-7.

 

Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl Am, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E. [Sheikh MY]. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomized, placebo-controlled trial. The LANCET, 2015; 385(9972): 956-65.

 

Dever JB, Sheikh MYReview article: spontaneous bacterial peritonitis - bacteriology, diagnosis, treatment, risk factors and prevention. Aliment Pharmacol Ther. 2015 Mar 26. doi: 10.1111/apt.13172. 

 

Alavi K, Atla, PR, Haq T, Sheikh MY. Coccidioidomycosis masquerading as eosinophilic ascites. Submitted to Case reports in Gastroenterology, May 2015.

 

Atla PR, Sheikh MY, Gill F, Kundu R, Choudhury J. Predictors of hospital re-admissions among Hispanics with hepatitis C-related cirrhosis. Manuscript submitted to Annals of Hepatology, May, 2015.

.

  Research:

A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy

SPONSOR: Valeant Pharmaceuticals
STATUS: Completed (MAR 2014)
TOTAL FUNDING: $38,181

 

A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects With Early Decompensated Liver Cirrhosis

SPONSOR: Valeant Pharmaceuticals
STATUS: Completed (APR 2015)
TOTAL FUNDING: $92,935

 

A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 Once Daily on Steatohepatitis in Patients With Non-Alcoholic Steatohepatitis (NASH)

SPONSOR: Genfit
STATUS: Completed (FEB 2015)
TOTAL FUNDING: $159,957

 

Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2

SPONSOR: NIH
STATUS: Completed (JUN 2016)
TOTAL FUNDING: $26,700

 

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis

SPONSOR: Intercept Pharmaceuticals
STATUS: Enrolling
TOTAL FUNDING: $80,820 (estimated)

 

A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis

SPONSOR: Conatus Pharmaceuticals
STATUS: IRB review
TOTAL FUNDING: $74,455 (estimated)

 

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis

SPONSOR: Genfit
STATUS: IRB review

TOTAL FUNDING: $168,928 (estimated